Latest Breaking News On - Tharimmune inc - Page 1 : comparemela.com

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomTirtht patelRandy milbyOmniab incTharimmune incExchange commissionChief executive officerPrivate securities litigation reform actRisk factorsAnnual reportClinical pharmacology

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.

United kingdomRandy milbyTirtht patelExchange commissionOmniab incTharimmune incChief executive officerPrivate securities litigation reform actRisk factorsAnnual reportClinical pharmacology

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

Randy milbyTharimmune incNews networkOmniab incAnnounces positive resultsHealthy subjectsChief executive officerLooking statementscertainPrivate securities litigation reform act

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.

United kingdomRandy milbyTirtht patelOmniab incTharimmune incExchange commissionChief executive officerPrivate securities litigation reform actRisk factorsAnnual reportClinical pharmacology

Tharimmune, Inc : Tharimmune to Present at 2024 BIO International Convention

BRIDGEWATER, NJ / ACCESSWIRE / May 29, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in

San diegoUnited statesTirth patelTirtht patelOmniab incTharimmune incInternational conventionCompany presentation theaterPresentation theaterOne partneringIhr portfolio